- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07949669
A Study of HLX105 in Patients With Advanced or Metastatic Solid Tumors
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX105 (Anti-PD-1 Antibody-IL-2 Variant Fusion Protein) in Advanced/Metastatic Solid Tumors
This is an open-label, first-in-human, Phase 1 study of HLX105, an anti-PD-1 antibody-IL-2 variant fusion protein, in adults with advanced or metastatic solid tumors that have progressed after standard treatment or for which no standard treatment is available. The main purpose is to evaluate the safety and tolerability of HLX105 and determine its maximum tolerated dose. The study will also assess how the body processes HLX105, whether antibodies against HLX105 develop, preliminary antitumor activity, and changes in immune cells and other biomarkers.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Waihan Ho
- Telefonnummer: +65-96253244
- E-post: Waihan_Ho@henlius.com
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Able to provide written informed consent and comply with study requirements.
- Aged 18-75 years.
- Histologically or cytologically confirmed advanced or metastatic solid tumors following failure of standard treatment, or for which no standard treatment is available.
- At least one measurable extracranial lesion according to RECIST v1.1.
- ECOG performance status of 0-1 and life expectancy greater than 3 months.
- Willing to provide adequate archived tumor tissue or undergo a tumor biopsy.
- Adequate organ function;
- Agreement to comply with protocol-defined contraception requirements during the study and for at least 6 months after the last dose.
Exclusion Criteria:
- Other malignancies within the past 2 years, except protocol-permitted early-stage cancers treated curatively.
- Prior IL-2/IL-15 therapy, or recent anticancer treatment, surgery, or live vaccination within protocol-defined washout periods.
- History of significant immunotherapy-related toxicity, severe allergic reactions, or allergy to HLX105 components.
- History or evidence of interstitial lung disease or other significant pulmonary conditions.
- Active infections, immunodeficiency, prior organ transplantation, or HBV/HCV infection meeting protocol-defined exclusion criteria.
- Significant cardiovascular, cerebrovascular, or thromboembolic disease.
- Brain metastases not meeting protocol-defined stability and eligibility requirements.
- Uncontrolled effusions or unresolved toxicity from prior treatment, except protocol-permitted conditions.
- Pregnancy or breastfeeding.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Dose Escalation
This study is an open-label first-in-human Phase I Clinical trial to evaluate the safety and tolerability of HLX105 with escalated doses in the treatment of participants with advanced/metastatic solid tumors. |
HLX105 will be administered as an intravenous(IV) infusion. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Dose-limiting toxicity (DLT)
Tidsram: The first 21 days starting with the first dose for participants dosed every 3 weeks, and the first 28 days starting with the first dose for participants dosed every 2 weeks.
|
The first 21 days starting with the first dose for participants dosed every 3 weeks, and the first 28 days starting with the first dose for participants dosed every 2 weeks.
|
|
Maximum tolerated dose(MTD)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Varaktighet av svar (DOR)
Tidsram: Upp till cirka 2 år
|
Upp till cirka 2 år
|
|
|
Number of participants with adverse events(AEs)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Number of participants with serious adverse events(SAEs)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Objective response rate(ORR)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Disease control rate(DCR)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Progression-free survival(PFS)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Overall survival(OS)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Cmax
Tidsram: Up to approximately 2 years
|
Maximum serum concentration (Cmax) of HLX105 |
Up to approximately 2 years
|
|
Tmax
Tidsram: Up to approximately 2 years
|
Time to maximum serum concentration (Tmax) of HLX105 |
Up to approximately 2 years
|
|
T1/2
Tidsram: Up to approximately 2 years
|
Half-life (T1/2) of HLX105 |
Up to approximately 2 years
|
|
Percentage of Participants With Anti-HLX105 Antibodies (ADA) and Percentage of Participants With Neutralizing Antibodies (NAb)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Change From Baseline in PD-1 Receptor Occupancy on Peripheral Blood T Cells
Tidsram: Up to approximately 2 years
|
Receptor occupancy will be expressed as the percentage of PD-1 receptors occupied by the study drug. Changes from baseline will be calculated at each scheduled post-dose assessment. |
Up to approximately 2 years
|
|
Change From Baseline in Peripheral Blood Interferon Gamma Concentration
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- HLX105-FIH101
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .